Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 2015;27(4):439–49.

Article  CAS  PubMed  Google Scholar 

Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23(5):295–316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer. 2023;23(4):193–215.

Article  PubMed  Google Scholar 

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.

Article  CAS  PubMed  Google Scholar 

Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775–90.

Article  PubMed  PubMed Central  Google Scholar 

Yang W, Liu S, Mao M, et al. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. J Exp Clin Cancer Res. 2024;43(1):38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donnell JS, Teng M, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–67.

Article  CAS  PubMed  Google Scholar 

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.

Article  CAS  PubMed  Google Scholar 

Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188–205.

Article  CAS  PubMed  Google Scholar 

Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.

Article  CAS  PubMed  Google Scholar 

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.

Article  PubMed  PubMed Central  Google Scholar 

Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol Ther. 2003;99(1):113–32.

Article  CAS  PubMed  Google Scholar 

Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends Cell Biol. 2019;29(5):396–416.

Article  CAS  PubMed  Google Scholar 

Kacen A, Javitt A, Kramer MP, et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat Biotechnol. 2023;41(2):239–51.

Article  CAS  PubMed  Google Scholar 

Zhu Q, Liu M, Dai L, et al. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2013;12(12):1123–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 2003;4(2):104–9.

Article  CAS  PubMed  Google Scholar 

Kalaora S, Wolf Y, Feferman T, et al. Combined analysis of antigen presentation and t-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 2018;8(11):1366–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vormehr M, Türeci Ö, Sahin U. Harnessing tumor mutations for truly individualized cancer vaccines. Annu Rev Med. 2019;70:395–407.

Article  CAS  PubMed  Google Scholar 

Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx681.

Article  PubMed  PubMed Central  Google Scholar 

Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–60.

Article  CAS  PubMed  Google Scholar 

Zhao T, Cai Y, Jiang Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8(1):283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of immunomodulatory immune synergies to adjuvant discovery and vaccine development. Trends Biotechnol. 2019;37(4):373–88.

Article  CAS  PubMed  Google Scholar 

Ammi R, De Waele J, Willemen Y, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120–31.

Article  CAS  PubMed  Google Scholar 

Chuang CC, Tsai MH, Yen HJ, et al. A fucoidan-quaternary chitosan nanoparticle adjuvant for anthrax vaccine as an alternative to CpG oligodeoxynucleotides. Carbohydr Polym. 2020;229: 115403.

Article  CAS  PubMed  Google Scholar 

Zhang X, Yang B, Ni Q, Chen X. Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev. 2023;52(9):2886–910.

Article  CAS  PubMed  Google Scholar 

Chen Q, Chen J, Yang Z, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31(10): e1802228.

Article  PubMed  Google Scholar 

Dymek M, Sikora E. Liposomes as biocompatible and smart delivery systems - the current state. Adv Colloid Interface Sci. 2022;309: 102757.

Article  CAS  PubMed  Google Scholar 

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

Article  CAS  PubMed  Google Scholar 

de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57(10):1569–77.

Article  CAS  PubMed